Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H6N4O3 |
| Molecular Weight | 182.1368 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)NC2=C(NC(=O)N2)C1=O
InChI
InChIKey=QFDRTQONISXGJA-UHFFFAOYSA-N
InChI=1S/C6H6N4O3/c1-10-4(11)2-3(9-6(10)13)8-5(12)7-2/h1H3,(H,9,13)(H2,7,8,12)
| Molecular Formula | C6H6N4O3 |
| Molecular Weight | 182.1368 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of allopurinol on theophylline metabolism and clearance. | 1979 Nov |
|
| Reversed-phase liquid chromatographic investigation of UV-absorbing low-molecular-weight compounds in saliva. | 1982 Dec 10 |
|
| Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease. | 1988 Sep |
|
| Human N-acetylation genotype determination with urinary caffeine metabolites. | 1990 Apr |
|
| Neurotoxic convulsions induced by theophylline and its metabolites in mice. | 1996 Jun |
|
| Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients. | 1999 Jan |
|
| The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. | 2001 Aug |
|
| Use of novel solid-phase extraction sorbent materials for high-performance liquid chromatography quantitation of caffeine metabolism products methylxanthines and methyluric acids in samples of biological origin. | 2001 Aug 15 |
|
| Caffeine metabolism before and after liver transplantation. | 2001 Feb |
|
| Xanthine oxidase activity and blood glutathione redox ratio in infants and children with septic shock syndrome. | 2001 Jan |
|
| Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis. | 2001 Jan |
|
| Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways. | 2001 Jan-Jun |
|
| [The acetylator polymorphism in a Khmer population: clinical consequences]. | 2001 Jul-Aug |
|
| Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. | 2001 Nov |
|
| Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects. | 2001 Sep |
|
| Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. | 2002 Dec |
|
| Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. | 2004 |
|
| Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study. | 2004 |
|
| Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. | 2004 Mar |
|
| Catabolism of caffeine in plants and microorganisms. | 2004 May 1 |
|
| Separation, pre-concentration, and HPLC analysis of methylxanthines in urine samples. | 2004 Oct |
|
| Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. | 2005 Jul |
|
| Inhibition of theophylline metabolism by suplatast and its metabolites in rats. | 2005 Jun |
|
| Improved HPLC assay for measuring serum vitamin C with 1-methyluric acid used as an electrochemically active internal standard. | 2005 Jun |
|
| Measurement of caffeine and five of the major metabolites in urine by high-performance liquid chromatography/tandem mass spectrometry. | 2005 Mar |
|
| Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism. | 2005 Nov |
|
| An unusual patient with kidney stones composed of 1-methyluric acid. | 2006 Feb |
|
| [Determination of the activity of cytochrome P-450 CYP2A6 by HPLC method with caffeine as metabolizing probe]. | 2006 Mar |
|
| Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. | 2006 May |
|
| Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats. | 2006 May 30 |
|
| In vitro antioxidant activity of coffee compounds and their metabolites. | 2007 Aug 22 |
|
| Theophylline and its metabolites produce a stimulating cholinergic effect on the small intestine and a nonadrenergic noncholinergic relaxing effect on the colon: a comparative study in the rabbit intestine. | 2007 Dec |
|
| In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. | 2007 Feb |
|
| Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. | 2007 Feb |
|
| Lack of effect of aciclovir on metabolism of theophylline and expression of hepatic cytochrome P450 1A2 in rats. | 2007 Mar |
|
| Anti-inflammatory effect of theophylline in rats and its involvement of the glucocorticoid-glucocorticoid receptor system. | 2008 Apr |
|
| Relaxing and contracting effects of theophylline's metabolites on the rabbit upper gastrointestinal tract. | 2008 Oct |
|
| Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? | 2009 Apr |
|
| Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. | 2009 Aug |
|
| Two distinct pathways for metabolism of theophylline and caffeine are coexpressed in Pseudomonas putida CBB5. | 2009 Jul |
|
| Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. | 2009 May |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:37:14 UTC 2023
by
admin
on
Fri Dec 15 18:37:14 UTC 2023
|
| Record UNII |
2WS4HQ639J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
708-79-2
Created by
admin on Fri Dec 15 18:37:14 UTC 2023 , Edited by admin on Fri Dec 15 18:37:14 UTC 2023
|
PRIMARY | |||
|
C030530
Created by
admin on Fri Dec 15 18:37:14 UTC 2023 , Edited by admin on Fri Dec 15 18:37:14 UTC 2023
|
PRIMARY | |||
|
69726
Created by
admin on Fri Dec 15 18:37:14 UTC 2023 , Edited by admin on Fri Dec 15 18:37:14 UTC 2023
|
PRIMARY | |||
|
211-905-7
Created by
admin on Fri Dec 15 18:37:14 UTC 2023 , Edited by admin on Fri Dec 15 18:37:14 UTC 2023
|
PRIMARY | |||
|
DTXSID70221063
Created by
admin on Fri Dec 15 18:37:14 UTC 2023 , Edited by admin on Fri Dec 15 18:37:14 UTC 2023
|
PRIMARY | |||
|
2WS4HQ639J
Created by
admin on Fri Dec 15 18:37:14 UTC 2023 , Edited by admin on Fri Dec 15 18:37:14 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
Hepatic biotransformation prior to excretion results in about equal amounts of 1-methylxanthine and 1-methyluric acid.
|
||
|
PARENT -> METABOLITE INACTIVE |
|
